false 0000811641 0000811641 2024-06-13 2024-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) June 13, 2024

 

ImmuCell Corporation
(Exact name of registrant as specified in its charter)

 

DE   001-12934   01-0382980
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

56 Evergreen Drive Portland, Maine   04103
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code 207-878-2770

 

 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, $0.10 par value per share   ICCC   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders

 

The 2024 Annual Meeting of Stockholders of the Company (the “2024 Annual Meeting”) was held by remote communication in the form of both a dial-in conference call and an audio webcast rather than an in-person event on Thursday, June 13, 2024, at 9:30 a.m. Eastern Time, for the following purposes:

 

1.To elect to one-year terms as Directors of the Company the seven nominees listed in the 2024 Proxy Statement.

 

2.To approve a non-binding advisory resolution on the Company’s executive compensation program.

 

3.To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2024.

 

At the 2024 Annual Meeting, there were present in person or by proxy 6,071,108 shares of the Company’s common stock, representing more than 78% of the total outstanding eligible votes. The final voting results for each proposal are as follows:

 

1.To elect to one-year terms as Directors of the Company the nominees listed in the Company’s Proxy Statement dated April 26, 2024:

 

   For   Withheld   Broker
Non-votes		 
Gloria J. Basse   3,893,437    528,614    1,649,057 
Michael F. Brigham   4,276,766    145,285    1,649,057 
Bobbi Jo Brockmann   3,990,836    431,215    1,649,057 
Bryan K. Gathagan   3,928,342    493,709    1,649,057 
Steven T. Rosgen   3,927,477    494,574    1,649,057 
David S. Tomsche   3,926,706    495,345    1,649,057 
Paul R. Wainman   3,911,027    511,024    1,649,057 

 

On the basis of this vote, each of the seven nominees was elected to a one-year term as a Director of the Company.

 

2.To approve a non-binding advisory resolution on the Company’s executive compensation program:

 

For  Against  Abstain  Broker Non-votes
4,013,133  114,706  294,212  1,649,057

 

66% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the non-binding advisory resolution on the Company’s executive compensation program was approved.

 

3.To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2024:

 

For  Against  Abstain  Broker Non-votes
6,041,186  10,089  19,833  0

 

99.5% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2024 was ratified.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 14, 2024 IMMUCELL CORPORATION
   
  By: /s/ Michael F. Brigham
    President, Chief Executive Officer
and Principal Financial Officer

 

 

2

 

 

v3.24.1.1.u2
Cover
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 13, 2024
Entity File Number 001-12934
Entity Registrant Name ImmuCell Corporation
Entity Central Index Key 0000811641
Entity Tax Identification Number 01-0382980
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 56 Evergreen Drive
Entity Address, City or Town Portland
Entity Address, State or Province ME
Entity Address, Postal Zip Code 04103
City Area Code 207
Local Phone Number 878-2770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.10 par value per share
Trading Symbol ICCC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
ImmuCell (NASDAQ:ICCC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas ImmuCell.
ImmuCell (NASDAQ:ICCC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas ImmuCell.